Showing results (1741-1750 of 2,288) with videos related to

Sort By:
Pageof 229
HIV Medicine|December 29, 2019
How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?M Metral, I Nadin, I Locatelli, et al.
HIV Medicine|December 19, 2019
Cardiovascular disease risk and its determinants in people living with HIV across different settings in South AfricaG V T Roozen, A G Vos, H A Tempelman, et al.
HIV Medicine|October 30, 2020
Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected childrenR Freguja, A Bamford, M Zanchetta, et al.
HIV Medicine|October 6, 2020
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, IndiaA Dravid, T P Betha, A K Sharma, et al.
HIV Medicine|July 29, 2021
The success of HIV combination prevention: The Dean Street modelNicolò Girometti, Valerie Delpech, Sheena McCormack, et al.
HIV Medicine|October 21, 2020
Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?L Gazzola, G Tagliaferri, A De Bona, et al.
HIV Medicine|June 14, 2022
Prescribing patterns of antiretroviral treatments during pregnancy for women living with HIV in Canada 2004-2020: A surveillance studySabrina Carvalho, Terry Lee, Karen J Tulloch, et al.
HIV Medicine|January 9, 2021
HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cARTC Horn, M Augustin, M S Ercanoglu, et al.
HIV Medicine|June 2, 2021
Relationship of polypharmacy to HIV RNA suppression in people aged ≥ 50 years living with HIVM M Murray, J Lin, A Buros Stein, et al.
HIV Medicine|December 22, 2022
Evaluating the effect of atorvastatin exposure and vitamin D levels on lipid outcomes in people with HIV-1 with suppressed HIV-1 RNA and LDL cholesterol <130 mg/dLFarah Rahman, Irena Brates, Francesca Aweeka, et al.
Pageof 229